Monday, November 23, 2009, 7:33PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares, Register

Aradigm Corp. (ARDM.OB)

On Nov 21: 0.16 USD   0.00 (0.00%)  
 MORE ON ARDM.OB 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 ARADIGM CORP (OTC BB:ARDM.OB) Delayed quote dataEdit
Last Trade:0.16 USD
Trade Time:Nov 21
Change: 0.00 (0.00%)
Prev Close:0.16
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:2.25
Day's Range:N/A - N/A
52wk Range:0.07 - 0.37
Volume:0
Avg Vol (3m):304,141
Market Cap:16.38M
P/E (ttm):N/A
EPS (ttm):-0.19
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ARDM.OB to Portfolio   Download Data

 HEADLINES 
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Business Wire (Mon, Nov 16)
ARADIGM CORP Financials
EDGAR Online Financials (Sat, Nov 14)
New Star Analyst Rankings for ARADIGM CORP
StarMine (Mon, Nov 9)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
Aradigm Announces Third Quarter 2009 Financial Results
Business Wire (Thu, Nov 5)
Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
Business Wire (Thu, Oct 22)
Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
Business Wire (Mon, Sep 14)
Emerging Stock Report Initiates Independent Research Coverage On Aradigm Corp.
GlobeNewswire (Wed, Sep 9)
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Aug 7)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Aug 7)
More Headlines for ARDM.OB...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.14
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices